Axcella Therapeutics ramps 200% on new U.S. patent to treat long COVID fatigue

  • Investing.com
Axcella Therapeutics ramps 200% on new U.S. patent to treat long COVID fatigue

Axcella Therapeutics (AXLA) surges 220% in pre-open trade after it was granted a U.S. patent to treat long COVID fatigue.

  • the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, particularly fatigue.
  • “Today’s issuance expands our global patent portfolio and Axcella’s protection of its lead candidate, AXA1125,” said Paul F. Fehlner, J.D., Ph.D., Senior Vice President, Chief Legal Officer of Axcella. “These patents and our entire portfolio are fully owned by Axcella.”

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles